Free shipping on all orders over $ 500

RO4987655

Cat. No. M9014
RO4987655 Structure
Synonym:

CH4987655

Size Price Availability Quantity
5mg USD 285  USD285 In stock
10mg USD 495  USD495 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

RO4987655 is an orally active and highly selective MEK inhibitor with an IC50 of 5.2 nM. RO4987655 inhibits proliferation of NCI-H2122 cells in a dose-dependent manner with an IC50 value of 0.0065 μM.

In vivo, RO4987655 is rapidly absorbed with a tmax of ~1 h. Female athymic nude mice are randomized into study groups. The tumors size is estimated with digital caliper and PET scans performed on days 0, 1, and 3 with 1.0, 2.5, and 5.0 mg/kg RO4987655. The vehicle treatment does not inhibit the NCI-H2122 tumor xenograft growth over this time frame. In contrast, RO4987655 treatment results in 119% tumor growth inhibition (TGI) at 1.0 mg/kg, 145% TGI at 2.5 mg/kg and 150% TGI at 5.0 mg/kg on day 3.

Protocol (for reference only)
Cell Experiment
Cell lines human lung adenocarcinoma cell line NCI-H2122
Preparation method The human lung adenocarcinoma cell line NCI-H2122 are maintained in the designated media and indicated concentrations of heat-inactivated fetal bovine serum and L-glutamine. Cells are grown at 37°C in an atmosphere of 5%CO2. Cells are treated with various concentrations of RO4987655 (0.00001, 0.001, 0.1, and 10 μM) for 72 h in 96-well plates and viable cells were quantified with Cell Counting Kit-8.
Concentrations 0.00001, 0.001, 0.1, and 10 μM
Incubation time 72 h
Animal Experiment
Animal models
Formulation
Dosages
Administration
Chemical Information
Molecular Weight 565.28
Formula C20H19F3IN3O5
CAS Number 874101-00-5
Solubility (25°C) DMSO: ≥ 30 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Tegnebratt T, et al. EJNMMI Res. Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [(18)F] FDG-PET imaging combined with proteomic approaches.

[2] Leijen S, et al. Clin Cancer Res. Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.

[3] Lee L, et al. Clin Cancer Res. The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of CH4987655 in healthy volunteers: target suppression using a biomarker.

Related MEK Products
Glycinexylidide

Glycinexylidide (GX) is the active metabolite of Lidocaine.

Xantocillin

Xantocillin (Xanthocillin X) is a marine agent extracted from Penicillium commune, induces autophagy through inhibition of the MEK/ERK pathway.

MEK-IN-6 hydrate

MEK-IN-6 hydrate is a MEK inhibitor.

MS934

MS934 is a novel improved VHL-recruiting MEK 1/2 degrader.

Nedometinib

Nedometinib is a tyrosine kinase inhibitor targeting to MEK1.

  Catalog
Abmole Inhibitor Catalog




Keywords: RO4987655, CH4987655 supplier, MEK, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.